Karjalainen, Riikka
Liu, Minxia
Kumar, Ashwini
He, Liye
Malani, Disha
Parsons, Alun
Kontro, Mika
Kallioniemi, Olli http://orcid.org/0000-0002-3231-0332
Porkka, Kimmo
Heckman, Caroline A.
Funding for this research was provided by:
Astra-Zeneca, Labcyte, Takara Biosciences and Pelago
Bristol-Myers Squibb, Celgene, Novartis and Pfizer
Celgene, Orion Pharma, Novartis, Oncopeptides, Innovative Medicines Initiatives 2 Project HARMONY
Article History
Received: 8 March 2019
Revised: 16 April 2019
Accepted: 23 April 2019
First Online: 7 June 2019
Compliance with ethical standards
:
: OK is a co-founder and a board member of Medisapiens and Sartar Therapeutics. He has received royalty on patents licensed from UC to Vysis-Abbot. His research group has a Vinnova-funded collaborative program with Astra-Zeneca, Labcyte, Takara Biosciences, and Pelago. KP has honoraria and grant support from Bristol-Myers Squibb, Celgene, Novartis, and Pfizer. CAH has received funding from Celgene, Orion Pharma, Novartis, Oncopeptides, and the Innovative Medicines Initiatives 2 project HARMONY. The other authors declare that they have no conflict of interest.